BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
Phenobarbital
,
rs7903146
,
GATA1
,
T cell differentiation
,
Arthritis
,
Leukocyte
,
Nosology
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
ZD1839
(compound)
Summary
General Info
Genetic Markers
Most Correlated Genes
No genes found
Explore Genetic Markers Results
Pathway Enrichment
Most Correlated Biogroups
No biogroups found
Explore Pathway Enrichment Results
Curated Studies
Most Correlated Studies
No studies found
Explore Curated Studies Results
Literature
Most Relevant Literature
ZD1839 and cisplatin alone or in combination for treatment of a nasopharyngeal carcinoma cell line a…
Gefitinib (ZD1839) increases the efficacy of cisplatin in ovarian cancer cells.
ZD1839 (IRESSA) stabilizes p27Kip1 and enhances radiosensitivity in cholangiocarcinoma cell lines.
Results of the Southwest Oncology Group phase II evaluation (study S0031) of ZD1839 for advanced tra…
Phase I trial of liposomal doxorubicin and ZD1839 in patients with refractory gynecological malignan…
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
Anastrozole and ZD1839 Compared With Fulvestrant and ZD1839 in Postmenopausal Women w/ Metastatic Br…
Safety and Effectiveness Study of Docetaxel and ZD1839 Followed by Removal of the Prostate to Treat …
ZD1839 (Iressa) for Recurrent or Metastatic Squamous Cell Carcinoma of the Skin
Phase II Study of Docetaxel + ZD1839 in Elderly Patients With Non-Small Cell Lung Cancer
An Open-label, Phase II Trial of ZD1839 (IRESSA) in Patients With Malignant Mesothelioma
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ